A Financial Services Association reporter learned today from Eli Lilly China that the price of tiverpotide in China has not yet been determined; it will be commercially marketed and announced in the fourth quarter of this year. At the same time, the company said that with the company's production site in North Carolina in the US and the expansion of production lines in other countries around the world, it will be able to expand production capacity in the next few years to meet the needs of patients around the world, and recently the production site in Alzey, Germany has also broken ground. Little note: Today, Eli Lilly China announced that Mu Fengda (titerpotide injection) has been approved for marketing in China. In addition, according to the Financial Services Association reporter's inquiry drug clinical trial registration and information disclosure platform, clinical trials of telpotide injection for weight loss indications in China are in phase III. (CFA Correspondent Wang Junxian, Lu Afeng)